Within Emerging Innovations I am working with a team of scientists to support the set up of external Open Innovations Platforms such as this MRC collaboration. We have to review the AZ portfolio of assets, in my case with a particularly close look at the safety profile, to establish which of our assets would be suitable to make available for external innovation activities. When proposals come in we consider them from a number of aspects, particularly the scientific credibility and novelty but also of course the risk benefit in the potential new disease area. I have been working closely with the external investigators to support them in their development of the protocols for this and other studies, and find it extremely stimulating to be researching and discussing such a diverse set of disease indications and trial designs with experts in their own field.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.